Covid-19 Antibody testing (IgG and IgM)
Diagnostic TestAntibody testing for previous exposure to Covid-19
NCT Number: NCT04347408
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to SARS-CoV-2.
Looking for future studies?
Notify Me1 month–15 year
All sexes
Observational
Royal Belfast Hospital for Sick Children, Belfast, United Kingdom
Coronaviruses are non-segmented positive-stranded RNA viruses with a roughly 30 kb genome. The majority of coronaviruses cause disease in a specific host species but some have infected humans by cross-species transmission. This process has led to a number of severe outbreaks of human disease including severe acute respiratory syndrome (SARS) in 2003 and Middle East respiratory syndrome (MERS) in 2012.
From December 2019 a novel infection "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) was identified in the Wuhan region of China. The infection was identified as the causal factor in a growing number of severe cases of pneumonia. This disease was subsequently named coronavirus disease 2019 (COVID-19) by World Health Organisation (WHO). SARS-CoV-2 has been shown to cause severe disease similar to the previous SARS coronavirus from 2003. Severe disease is associated with pneumonia and damage to vital organs including lung, heart, liver, and kidney.
Fortunately SARS-CoV-2 appears to cause only mild, or no, symptoms in children.
The social distancing measures in the United Kingdom include the closure of schools and the cancelling of routine paediatric clinics. These drastic, but necessary, steps are likely to have a profound effect on the well-being of children.
This study is required to determine what proportion of children have been exposed to SARS-Cov-2 and how many, if any, have neutralizing antibodies. The findings from this study could be used to inform public health decisions regarding the re-opening of schools and other services vital to the well-being of children.
In addition the study will recruit children with paediatric multi-system inflammatory syndrome admitted to the Royal Belfast Hospital for Sick Children along with matched controls with other infections.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Healthy children of healthcare professionals.
Exclusion criteria
Not currently receiving antibiotics, not admitted to hospital within the last seven days, not receiving immunosuppressive drugs and never diagnosed with a malignancy.
Admitted children with paediatric multisystem inflammatory syndrome and admitted children with other serious infections.
Antibody testing for previous exposure to Covid-19
Storage of blood for multi-omics analysis
Time frame: 6 months
Time frame: 6 months
Measure of cardiac function
Time frame: 6 months
Cardiac Enzyme
Time frame: 6 months
Cardiac enzyme
Queen's University, Belfast
Other
Seroprevalence of SARS-Cov-2 Antibodies in Children - a Prospective Multicentre Cohort Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04407143
COVID, COVID-19
A Coruña, Spain
View Trial DetailsNCT04335084
COVID, COVID-19
Ventura, California, United States
View Trial DetailsNCT04482686
COVID, COVID-19
Ventura, California, United States
View Trial DetailsNCT04368143
B Cell, COVID
Antwerp, Belgium
View Trial Details